PEMRAMETOSTAT SUCCINATE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H32N6O3.C4H6O4
Molecular Weight	570.6373
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.CC(=O)N1CCC(CC1)NC2=CC(=NC=N2)C(=O)NC[C@H](O)CN3CCC4=CC=CC=C4C3

InChI

InChIKey=GXLSVNOMQNNGQM-BOXHHOBZSA-N

InChI=1S/C24H32N6O3.C4H6O4/c1-17(31)30-10-7-20(8-11-30)28-23-12-22(26-16-27-23)24(33)25-13-21(32)15-29-9-6-18-4-2-3-5-19(18)14-29;5-3(6)1-2-4(7)8/h2-5,12,16,20-21,32H,6-11,13-15H2,1H3,(H,25,33)(H,26,27,28);1-2H2,(H,5,6)(H,7,8)/t21-;/m0./s1

HIDE SMILES / InChI

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Protein arginine N-methyltransferase 5 2 Target ID: CHEMBL1795116 Sources: https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140626&CC=WO&NR=2014100719A2&KC=A2	Inhibitor 8504

C_max

Value	Dose	Analyte	Population
1322.8 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
960.4 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1125.4 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
889.7 ng/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
7128.4358 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6572.8527 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9202.5641 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6397.084 ng × h/mL CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.0755 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.7688 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.2694 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.8437 h CLINICAL TRIAL https://clinicaltrials.gov/study/NCT03614728?term=GSK-3326595&rank=1&tab=results	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	EPZ-015938 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Name

Type

Language

PEMRAMETOSTAT SUCCINATE

Common Name

English

BUTANEDIOIC ACID, COMPD. WITH 6-((1-ACETYL-4-PIPERIDINYL)AMINO)-N-((2S)-3-(3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXYPROPYL)-4-PYRIMIDINECARBOXAMIDE (1:1)

Preferred Name

English

GSK-3326595 SUCCINATE

Common Name

English

Code System Code Type Description

CAS

1848944-46-6

Created by admin on Mon Mar 31 23:17:38 GMT 2025 , Edited by admin on Mon Mar 31 23:17:38 GMT 2025

PRIMARY

FDA UNII

483UNX1IFR

Created by admin on Mon Mar 31 23:17:38 GMT 2025 , Edited by admin on Mon Mar 31 23:17:38 GMT 2025

PRIMARY

PUBCHEM

154572871

Created by admin on Mon Mar 31 23:17:38 GMT 2025 , Edited by admin on Mon Mar 31 23:17:38 GMT 2025

PRIMARY

ACTIVE MOIETY


					VXT8SZ6875

PEMRAMETOSTAT

SUBSTANCE RECORD


					483UNX1IFR

PEMRAMETOSTAT SUCCINATE

Details

SMILES

InChI

Approval Year

Targets

Cmax

AUC

T1/2

Overview

OverviewOther

C_max

T_1/2